# Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension

Study · id `cardio:ct-nct01756430` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01756430](<https://clinicaltrials.gov/study/NCT01756430>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01756430

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 238 participants.

## Technical summary

Registry record NCT01756430. Randomized; triple masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2013-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 238 participants (enrolled count; ClinicalTrials.gov record NCT01756430, source copy `cardio:ctgov-nct01756430-2014-01-14`, retrieved 2026-10-26)
- Start date: 2012-12 (registry gives no type) (ClinicalTrials.gov record NCT01756430, source copy `cardio:ctgov-nct01756430-2014-01-14`, retrieved 2026-10-26)
- Primary completion: 2013-09 (actual) (ClinicalTrials.gov record NCT01756430, source copy `cardio:ctgov-nct01756430-2014-01-14`, retrieved 2026-10-26)
- Completion: 2013-09 (actual) (ClinicalTrials.gov record NCT01756430, source copy `cardio:ctgov-nct01756430-2014-01-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01756430, source copy `cardio:ctgov-nct01756430-2014-01-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01756430-2014-01-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension
- Condition: Hypertension
- Intervention (Drug): Carvedilol SR 32mg, QD
- Intervention (Drug): Carvedilol SR 64mg, QD
- Intervention (Drug): Carvedilol IR 25mg, QD
- Intervention (Drug): Carvedilol IR 25mg, BID
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: f9fd7ce1ca57f7419fb965434896d94c7261a92f863d9f4fb5697bb148808956
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
